CNBX Pharmaceuticals Inc. CNBX has acquired a majority stake in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company and the co-founding professor Benjamin Dekel (MD, PhD) will continue to serve as the company’s chief scientist; CNBX President, Gabriel Yarivto assume the position of CEO of TaGeza Biopharmaceuticals.
TaGeza is a developer of next-generation immunotherapies and targeted cancer therapies. The company is currently developing new antibody-drug conjugates based on novel monoclonal antibodies, targeting specific types of cancer by targeting the highly tumorigenic cancer cell subpopulation, called cancer stem cells or tumor initiating cells. Patients undergoing more conventional therapies such as chemotherapy benefit from a reduction in tumor size but can often relapse and even develop more aggressive disease, in part due to the residual population of chemotherapy-resistant tumor cells that are enriched with cancer stem cells or tumor initiating cells. Therefore, targeting cancer stem cells or tumor-initiating cells may help improve patient outcomes and reduce relapses caused by their aggressive self-renewal and tumor properties as well as their resistance to more conventional therapies.
CNBX Pharmaceuticals is an American public company and developer of cancer-related cannabinoid drugs. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.
Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss any important developments in the industry.
Photo: Benzinga; Sources: Courtesy of Matthias Zomer via Pexels, squarefrog via Pixabay